Drug Trial Radar · NCT07637942
Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Oct 1, 2026
Primary completion
Apr 22, 2028
Study completion Apr 22, 2028
Sponsor
- Lead sponsor
- International Maternal Pediatric Adolescent AIDS Clinical Trials GroupResearch network
- Sponsor type
- Research network
- Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Mental Health (NIMH)
- First posted
- Jun 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase IV, multi-site, open-label, non-randomized study of the pharmacokinetics (PK) of long-acting injectable cabotegravir and rilpivirine (CAB LA + RPV LA) during pregnancy and postpartum.
Conditions
- HIV -1 Infection
Interventions
Every 4-week long-acting injectable cabotegravir and rilpivirineDrug
Long-acting injectable cabotegravir and rilpivirine, initiated pre-conception. Participants will receive these drugs as prescribed outside the study by their non-study clinical care provider.
Every 4-week long-acting injectable cabotegravir and rilpivirineDrug
Long-acting injectable cabotegravir and rilpivirine, initiated post-conception. Participants will receive these drugs as prescribed outside the study by their non-study clinical care provider.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Population PK: geometric mean clearance of CAB and RPV in second trimester, third trimester, and postpartum derived from a population PK modelTime frame: Measured from study entry through six weeks postpartum
- Geometric mean pharmacokinetic trough of CAB and RPV from every 4 week (Q4W) CAB LA and RPV LA measured every 4 weeks in plasma in second trimester, third trimester, and postpartumTime frame: Measured from study entry through six weeks postpartum
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Site 4601, University of California, UC San Diego CRS
La Jolla, California · Not yet recruiting
Site 5048, University of Southern California
Los Angeles, California · Not yet recruiting
Site 5052, University of Colorado
Aurora, Colorado · Recruiting
Site 5030, Emory University School of Medicine
Atlanta, Georgia · Not yet recruiting
Site 4001, Lurie Children's Hospital of Chicago CRS
Chicago, Illinois · Recruiting
Site 5092, Johns Hopkins University
Baltimore, Maryland · Not yet recruiting
Site 5013, Jacobi Medical Center Bronx
The Bronx, New York · Not yet recruiting
Site 6201, University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
Site 6501, St Jude Children's Research Hospital
Memphis, Tennessee · Not yet recruiting
Site 5128, Baylor College of Medicine/Texas Children's Hospital
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.